RWE on Patients With mPDAC Long-term Survival After Treatment With Liposomal Irinotecan
The objective is to describe mPDAC patients still alive one year after the first cycle of nal-IRI
Pancreatic Cancer Metastatic
Disease characteristic according to age, Tumor stage (localized/locally advanced/metastatic), Through study completion (approximatively 5 months)
The objectives on patients still alive one year after the first cycle of nal-IRI :

* Characterize mPDAC patient population according to their demographics
* Identify PDAC treatment by line of treatment from diagnosis to last treatment
* Explore prognostic factors of longer Overall Survival (OS) and Progression Free Survivor (PFS) among mPDAC patients showing long-term Survival